[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582431":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":29,"centralContacts":36,"locations":42,"responsibleParty":56,"collaborators":29,"id":60,"slug":29,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":29,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":29,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":82,"whyStopped":29,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Medipol University","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Ozone Therapy Group","EXPERIMENTAL","Patients received 50 mL ozonated saline (20-40 µg\u002FmL) intravesically twice weekly for 3 weeks.",[13],"Other: Intravesical Ozone Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.",[19],"Other: Placebo (Normal Saline)",{"label":21,"type":6,"description":22,"interventionNames":23},"Control Group","Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.",[24],"Other: Control",[26,30,33],{"type":6,"name":27,"description":11,"armGroupLabels":28,"otherNames":29},"Intravesical Ozone Therapy",[9],null,{"type":6,"name":31,"description":17,"armGroupLabels":32,"otherNames":29},"Placebo (Normal Saline)",[15],{"type":6,"name":34,"description":22,"armGroupLabels":35,"otherNames":29},"Control",[21],[37],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},"Ali İhsan Memmi","CONTACT","90 0537 922 0997","alimemmi@gmail.com",[43],{"facility":44,"status":29,"city":45,"state":29,"zip":29,"country":46,"countryCode":29,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"İstanbul Başakşehir Çam Ve Sakura Şehir Hastanesi","Istanbul","Turkey (Türkiye)",{"type":48,"coordinates":49},"Point",[50,51],28.94966,41.01384,{"lat":51,"lon":50},[54],{"name":38,"role":39,"phone":55,"phoneExt":29,"email":41},"+90 537 922 0997",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Ali Ihsan Memmi","urologist","100582431",false,"NCT06863220","Intravesical Ozone Therapy for Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* Age 18-65 years\n* Histopathologically or clinically confirmed IC (per AUA guidelines)\n* Symptoms for at least 6 months\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Bladder malignancy\n* Pregnancy or breastfeeding\n* Known ozone allergy\n* Intravesical therapy within 3 months\n* G6PD deficiency","ALL","18 Years","65 Years",{"count":69,"type":70},60,"ESTIMATED","INTERVENTIONAL",[73],"NA","This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.",[76,77],"Interstitial Cystitis","Bladder Pain Syndrome",[76,79,80,81],"bladder pain syndrome","ozone therapy","intravesical ozone","NOT_YET_RECRUITING","2025-04-23",{"date":85,"type":86},"2025-04-27","ACTUAL",{"date":88,"type":70},"2025-06-01",{"date":90,"type":70},"2026-06-01",{"name":5,"class":6},1]